|
1.
|
|
8 p, 1.3 MB |
Longitudinal study on nerve ultrasound and corneal confocal microscopy in NF155 paranodopathy
/
Athanasopoulos, D. (Ruhr-University) ;
Motte, J. (Ruhr-University) ;
Fisse, A.L. (Ruhr-University) ;
Grueter, T. (Ruhr-University) ;
Trampe, N. (Katholische Kliniken Emscher-Lippe) ;
Sturm, D. (Ruhr University) ;
Tegenthoff, M. (Ruhr University) ;
Sgodzai, M. (Ruhr-University) ;
Klimas, R. (Ruhr-University) ;
Querol, Luis (Institut d'Investigació Biomèdica Sant Pau) ;
Gold, R. (Ruhr-University) ;
Pitarokoili, K. (Ruhr-University) ;
Universitat Autònoma de Barcelona
We report the case of a 27-year-old patient with subacute anti-neurofascin-155 neuropathy with bifacial palsy, who showed excellent response to rituximab. We provide longitudinal data of established clinical scores, nerve conduction studies, antibody titers, and novel imaging methods (nerve ultrasonography and corneal confocal microscopy). [...]
2020 -  10.1002/acn3.51061
Annals of Clinical and Translational Neurology, Vol. 7 Núm. 6 (january 2020) , p. 1061-1068
|
|
|
2.
|
|
11 p, 715.9 KB |
Predicting Impulse Control Disorders in Parkinson Disease through Incentive Biomarkers
/
Marín-Lahoz, Juan (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Martinez-Horta, Saul (Institut d'Investigació Biomèdica Sant Pau) ;
Pagonabarraga Mora, Javier (Institut d'Investigació Biomèdica Sant Pau) ;
Horta, Andrea (Institut d'Investigació Biomèdica Sant Pau) ;
Aracil-Bolaños, Ignacio (Institut d'Investigació Biomèdica Sant Pau) ;
Bejr-kasem, Helena (Network Research Center-Neurodegenerative Diseases (CIBERNED)) ;
Sampedro, Frederic (Institut d'Investigació Biomèdica Sant Pau) ;
Campolongo, Antonia (Institut d'Investigació Biomèdica Sant Pau) ;
Kulisevsky, Jaime (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Objective: This study was undertaken to evaluate whether the feedback-related negativity (FRN)-a neurophysiological marker of incentive processing-can be used to predict the development of impulse control disorders (ICDs) in Parkinson disease (PD). [...]
2022 - 10.1002/ana.26486
Annals of neurology, Vol. 92 Núm. 6 (december 2022) , p. 974-984
|
|
|
3.
|
|
13 p, 967.0 KB |
Seizures after Ischemic Stroke : A Matched Multicenter Study
/
Ferreira-Atuesta, Carolina (Icahn School of Medicine at Mount Sinai) ;
Döhler, Nico (Specialist Clinic for Neurorehabilitation) ;
Erdélyi-Canavese, Barbara (Kantonsspital St. Gallen) ;
Felbecker, Ansgar (Kantonsspital St. Gallen) ;
Siebel, Philip (Kantonsspital St. Gallen) ;
Scherrer, Natalie (University Hospital and University of Zurich) ;
Bicciato, Giulio (University Hospital and University of Zurich) ;
Schweizer, Juliane (University Hospital and University of Zurich) ;
Sinka, Lucia (University Hospital and University of Zurich) ;
Imbach, Lukas L. (University Hospital and University of Zurich) ;
Katan, Mira (University of Zurich) ;
Abraira del Fresno, Laura (Hospital Universitari Vall d'Hebron) ;
Santamarina, Estevo (Hospital Universitari Vall d'Hebron) ;
Álvarez Sabín, José (Hospital Universitari Vall d'Hebron) ;
Winklehner, Michael (Medical University of Vienna) ;
von Oertzen, Tim J. (Kepler Universitätsklinikum) ;
Wagner, Judith N. (Kepler Universitätsklinikum) ;
Gigli, Gian Luigi (University of Udine and Clinical Neurology) ;
Serafini, Anna (University of Udine and Clinical Neurology) ;
Janes, Francesco (University of Udine and Clinical Neurology) ;
Merlino, Giovanni (University of Udine and Clinical Neurology) ;
Valente, Mariarosaria (University of Udine and Clinical Neurology) ;
Gregoraci, Giorgia (University of Udine) ;
Conrad, Julian (Ludwig Maximilians University of Munich) ;
Evers, Stefan (Krankenhaus Lindenbrunn) ;
Lochner, Piergiorgio (Saarland University Medical Center) ;
Roell, Frauke (Saarland University Medical Center) ;
Brigo, Francesco (Hospital of Merano-Meran (SABES-ASDAA)) ;
Bentes, Carla (Hospital de Santa Maria-CHLN) ;
Peralta, Ana Rita (Hospital de Santa Maria-CHLN) ;
Melo, Teresa Pinho e (Hospital de Santa Maria-CHLN) ;
Keezer, Mark R. (Centre Hospitalier de l'Université de Montréal) ;
Duncan, John S. (Chalfont Centre for Epilepsy) ;
Sander, Josemir W. (West of China Hospital) ;
Tettenborn, Barbara (Kantonsspital St. Gallen) ;
Koepp, Matthias J. (Chalfont Centre for Epilepsy) ;
Galovic, Marian (Chalfont Centre for Epilepsy) ;
Universitat Autònoma de Barcelona
The purpose of this study was to identify risk factors for acute symptomatic seizures and post-stroke epilepsy after acute ischemic stroke and evaluate the effects of reperfusion treatment. We assessed the risk factors for post-stroke seizures using logistic or Cox regression in a multicenter study, including adults from 8 European referral centers with neuroimaging-confirmed ischemic stroke. [...]
2021 - 10.1002/ana.26212
Annals of neurology, Vol. 90 (september 2021) , p. 808-820
|
|
|
4.
|
|
14 p, 1.4 MB |
A transient inflammatory response contributes to oxaliplatin neurotoxicity in mice
/
Calls, Aina (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Torres Espín, Abel (University of California San Francisco) ;
Tormo, Marc (Universitat Pompeu Fabra) ;
Martínez-Escardó, Laura (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
Bonet, Núria (Universitat Pompeu Fabra) ;
Casals, Ferran (Universitat de Barcelona) ;
Navarro, X. (Xavier) (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Yuste Mateos, Víctor J. (Víctor José) (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
Udina i Bonet, Esther (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Bruna, Jordi (Universitat Autònoma de Barcelona. Institut de Neurociències)
Peripheral neuropathy is a relevant dose-limiting adverse event that can affect up to 90% of oncologic patients with colorectal cancer receiving oxaliplatin treatment. The severity of neurotoxicity often leads to dose reduction or even premature cessation of chemotherapy. [...]
2022 - 10.1002/acn3.51691
Annals of Clinical and Translational Neurology, Vol. 9, Num. 12 (November 2022) , p. 1985-1998
|
|
|
5.
|
|
14 p, 2.8 MB |
Dystrophinopathy Phenotypes and Modifying Factors in Exon 45-55 Deletion
/
Poyatos-García, Javier (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Martí, Pilar (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Liquori, Alessandro (Centre for Biomedical Network Research on Cancer) ;
Muelas, Nuria (Hospital Universitari i Politècnic La Fe (València)) ;
Pitarch, Inmaculada (Hospital Universitari i Politècnic La Fe (València)) ;
Martinez-Dolz, Luis (Centre for Biomedical Network Research on Cardiovascular Diseases) ;
Rodríguez, Benjamin (Institut d'Investigació Biomèdica Sant Pau) ;
Gonzalez-Quereda, L (Institut d'Investigació Biomèdica Sant Pau) ;
Damiá, Maria (Hospital Universitari i Politècnic La Fe (València)) ;
Aller, Elena (Hospital Universitari i Politècnic La Fe (València)) ;
Selva-Gimenez, Marta (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Vilchez, Roger (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Diaz-Manera, Jordi (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Alonso-Pérez, Jorge (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Bárcena LLona, Jose Eulalio (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Jauregui, Amaia (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Gamez, Josep (Universitat Autònoma de Barcelona) ;
Aladrén, Jesus Angel (Calahorra Hospital Foundation) ;
Fernández, Ariadna (Calahorra Hospital Foundation) ;
Montolio, Marisol ;
Azorin, Inmaculada (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Hervas, David (Universitat Politècnica de València) ;
Casasús, Ana (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Nieto, Marisa (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Gallano, Pia (Institut d'Investigació Biomèdica Sant Pau) ;
Sevilla, Teresa (Universitat de València) ;
Vílchez, Juan J (Universitat de València)
Duchenne muscular dystrophy (DMD) exon 45-55 deletion (del45-55) has been postulated as a model that could treat up to 60% of DMD patients, but the associated clinical variability and complications require clarification. [...]
2022 - 10.1002/ana.26461
Annals of neurology, Vol. 92 (september 2022) , p. 793-806
|
|
|
6.
|
|
10 p, 924.1 KB |
Real-world evaluation of ocrelizumab in multiple sclerosis : A systematic review
/
Montalban, Xavier (Hospital Universitari Vall d'Hebron) ;
Matthews, Paul M. (UK Dementia Research Institute Centre at Imperial College London) ;
Simpson, Alex (F. Hoffmann-La Roche) ;
Petrie, John L. (PHMR Ltd) ;
Sammon, Cormac (PHMR Ltd) ;
Ramagopalan, Sreeram (F. Hoffmann-La Roche) ;
Disanto, Giulio (Ente Ospedaliero Cantonale) ;
Kuhle, Jens (University of Basel) ;
Universitat Autònoma de Barcelona
Across its clinical development program, ocrelizumab demonstrated efficacy in improving clinical outcomes in multiple sclerosis, including annualized relapse rates and confirmed disability progression. [...]
2023 - 10.1002/acn3.51732
Annals of Clinical and Translational Neurology, Vol. 10 Núm. 3 (march 2023) , p. 302-311
|
|
|
7.
|
|
15 p, 1.7 MB |
Preliminary validity of the Draw a Shape Test for upper extremity assessment in multiple sclerosis
/
Graves, Jennifer S. (University of California San Diego) ;
Ganzetti, Marco (F. Hoffmann-La Roche Ltd, Basel) ;
Dondelinger, Frank (F. Hoffmann-La Roche Ltd, Basel) ;
Lipsmeier, Florian (F. Hoffmann-La Roche Ltd, Basel) ;
Belachew, Shibeshih (F. Hoffmann-La Roche Ltd, Basel) ;
Bernasconi, Corrado (F. Hoffmann-La Roche Ltd, Basel) ;
Montalban, Xavier (Hospital Universitari Vall d'Hebron) ;
Beek, Johan van (F. Hoffmann-La Roche Ltd, Basel) ;
Baker, Michael (F. Hoffmann-La Roche Ltd, Basel) ;
Gossens, Christian (F. Hoffmann-La Roche Ltd, Basel) ;
Lindemann, Michael (F. Hoffmann-La Roche Ltd, Basel) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Objective To validate the smartphone sensor-based Draw a Shape Test - a part of the Floodlight Proof-of-Concept app for remotely assessing multiple sclerosis-related upper extremity impairment by tracing six different shapes. [...]
2023 - 10.1002/acn3.51705
Annals of Clinical and Translational Neurology, Vol. 10 Núm. 2 (2023) , p. 166-180
|
|
|
8.
|
|
14 p, 2.2 MB |
Associations of with clinico-radiological measures in a large population
/
Sotirchos, Elias S. (Johns Hopkins University School of Medicine) ;
Fitzgerald, Kathryn (Johns Hopkins University School of Medicine) ;
Singh, Carol (Biogen) ;
Smith, Matthew D. (Johns Hopkins University School of Medicine) ;
Reyes-Mantilla, Maria (Johns Hopkins University School of Medicine) ;
Hersh, Carrie (Cleveland Clinic) ;
Hyland, Megan H. (University of Rochester Medical Center) ;
Canissario, Ryan (University of Rochester Medical Center) ;
Simmons, Sarah B. (Mellen Center, Neurological Institute, Cleveland Clinic) ;
Arrambide, Georgina (Hospital Universitari Vall d'Hebron) ;
Montalban, Xavier (Hospital Universitari Vall d'Hebron) ;
Comabella, Manuel (Hospital Universitari Vall d'Hebron) ;
Naismith, Robert (Washington University in St. Louis) ;
Qiao, Min (Washington University in St. Louis) ;
Krupp, Lauren B. (New York University) ;
Nicholas, Jacqueline A. (Riverside Methodist Hospital) ;
Akgün, Katja (University Clinic Carl-Gustav Carus) ;
Ziemssen, Tjalf (University Clinic Carl-Gustav Carus) ;
Rudick, Richard ((formerly) Biogen) ;
Fisher, Elizabeth (Biogen) ;
Bermel, Robert (Mellen Center, Neurological Institute, Cleveland Clinic) ;
Mowry, Ellen (Johns Hopkins University School of Medicine) ;
Calabresi, Peter A. (Johns Hopkins University School of Medicine) ;
Universitat Autònoma de Barcelona
Evaluation of serum neurofilament light chain (sNfL), measured using high-throughput assays on widely accessible platforms in large, real-world MS populations, is a critical step for sNfL to be utilized in clinical practice. [...]
2022 - 10.1002/acn3.51704
Annals of Clinical and Translational Neurology, Vol. 10 (november 2022) , p. 84-97
|
|
|
9.
|
|
8 p, 1.1 MB |
Accelerated long-term forgetting over three months in asymptomatic APOE ɛ4 carriers
/
Tort-Merino, Adrià (Institute of Neurosciences. University of Barcelona) ;
Laine, Matti J. (Department of Psychology. Åbo Akademi University) ;
Valech, Natalia (Hospital Clínic i Provincial de Barcelona) ;
Olives, Jaume (Institute of Neurosciences. University of Barcelona) ;
León, María (Hospital Clínic i Provincial de Barcelona) ;
Ecay-Torres, Mirian (Centro de Investigación y Tecnología Agroalimentaria de Aragón) ;
Estanga, Ainara (Centro de Investigación y Tecnología Agroalimentaria de Aragón) ;
Martinez-Lage, Pablo (Centro de Investigación y Tecnología Agroalimentaria de Aragón) ;
Fortea, Juan (Institut d'Investigació Biomèdica Sant Pau) ;
Sanchez-Valle, Raquel (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Rami Gonzalez, Lorena (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Rodríguez-Fornells, Antoni (Institució Catalana de Recerca i Estudis Avançats)
Accelerated long-term forgetting (ALF) refers to a rapid loss of information over days or weeks despite normal acquisition/encoding. Notwithstanding its potential relevance as a presymptomatic marker of cognitive dysfunction, no study has addressed the relationship between ALF and Alzheimer's disease (AD) biomarkers. [...]
2021 - 10.1002/acn3.51245
Annals of Clinical and Translational Neurology, Vol. 8 Núm. 2 (february 2021) , p. 477-484
|
|
|
10.
|
|
12 p, 2.7 MB |
Assessing Dysferlinopathy Patients Over Three Years With a New Motor Scale
/
Jacobs, M.B. (Pediatrics. Epidemiology. and Biostatistics. George Washington University) ;
James, Meredith K (The John Walton Muscular Dystrophy Research Centre. Translational and Clinical Research Institute. Newcastle University and Newcastle Hospitals NHS Foundation Trust. Central Parkway) ;
Lowes, Linda P (The Abigail Wexner Research Institute at Nationwide Children's Hospital) ;
Alfano, Lindsay N (The Abigail Wexner Research Institute at Nationwide Children's Hospital) ;
Eagle, M. (The John Walton Muscular Dystrophy Research Centre. Translational and Clinical Research Institute. Newcastle University and Newcastle Hospitals NHS Foundation Trust. Central Parkway) ;
Muni Lofra, R. (The John Walton Muscular Dystrophy Research Centre. Translational and Clinical Research Institute. Newcastle University and Newcastle Hospitals NHS Foundation Trust. Central Parkway) ;
Moore, U. (The John Walton Muscular Dystrophy Research Centre. Translational and Clinical Research Institute. Newcastle University and Newcastle Hospitals NHS Foundation Trust. Central Parkway) ;
Feng, J. (Center for Translational Science. Division of Biostatistics and Study Methodology. Children's National Health System) ;
Rufibach, L.E. (The Jain Foundation) ;
Rose, K. (The Children's Hospital at Westmead. The University of Sydney) ;
Duong, T. (Lucile Salter Packard Children's Hospital at Stanford) ;
Bello, Luca (Department of Neuroscience. University of Padova) ;
Pedrosa-Hernández, Irene (Institut d'Investigació Biomèdica Sant Pau) ;
Holsten, Scott (Neuroscience Institute. Carolinas Neuromuscular/ALS-MDA Center. Carolinas HealthCare System) ;
Sakamoto, C. (Department of Physical Rehabilitation. National Center Hospital. National Center of Neurology and Psychiatry) ;
Canal, Aurélie (Institut de Myologie. AP-HP. GH Pitié-Salpêtrière) ;
Sanchez-Aguilera Práxedes, N. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Thiele, S. (Friedrich-Baur-Institute. Department of Neurology. Ludwig-Maximilians University of Munich) ;
Siener, C. (Department of Neurology Washington University School of Medicine) ;
Vandevelde, B. (Service des Maladies Neuromusculaire et de la SLA. Hôpital de La Timone) ;
DeWolf, Brittney (Cooperative International Neuromuscular Research Group (CINRG). Children's National Health System) ;
Maron, E. (ELAN-PHYSIO. Praxis für Physiotherapie Maron) ;
Guglieri, M. (The John Walton Muscular Dystrophy Research Centre. Translational and Clinical Research Institute. Newcastle University and Newcastle Hospitals NHS Foundation Trust. Central Parkway) ;
Hogrel, J.Y. (Institut de Myologie (París, França)) ;
Blamire, Andrew (Magnetic Resonance Centre. Institute for Cellular Medicine. Newcastle University) ;
Carlier, Pierre G (AIM & CEA NMR Laboratory. Institute of Myology. Pitié-Salpêtrière University Hospital) ;
Spuler, S. (Charite Muscle Research Unit. Experimental and Clinical Research Center. a joint cooperation of the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine) ;
Day, John W (Department of Neurology and Neurological Sciences. Stanford University School of Medicine) ;
Jones, K.J. (The Children's Hospital at Westmead. The University of Sydney) ;
Bharucha-Goebel, Diana (National Institutes of Health (Bethesda, Estats Units d'Amèrica)) ;
Salort-Campana, E. (Service des Maladies Neuromusculaire et de la SLA. Hôpital de La Timone) ;
Pestronk, Alan (Washington University School of Medicine) ;
Walter, Maggie C (Friedrich-Baur-Institute. Department of Neurology. Ludwig-Maximilians University of Munich) ;
Paradas, C. (Instituto de Biomedicina de Sevilla) ;
Stojkovic, T. (Institut de Myologie. AP-HP. GH Pitié-Salpêtrière) ;
Mori-Yoshimura, Madoka (National Center of Neurology and Psychiatry Tokyo) ;
Bravver, Elena (Neuroscience Institute. Carolinas Neuromuscular/ALS-MDA Center. Carolinas HealthCare System) ;
Diaz-Manera, Jordi (Institut d'Investigació Biomèdica Sant Pau) ;
Pegoraro, Elena (University of Padova) ;
Mendell, J. R. (The Abigail Wexner Research Institute at Nationwide Children's Hospital) ;
Mayhew, A.G. (The John Walton Muscular Dystrophy Research Centre. Translational and Clinical Research Institute. Newcastle University and Newcastle Hospitals NHS Foundation Trust. Central Parkway) ;
Straub, Volker (The John Walton Muscular Dystrophy Research Centre. Translational and Clinical Research Institute. Newcastle University and Newcastle Hospitals NHS Foundation Trust. Central Parkway)
Objective: Dysferlinopathy is a muscular dystrophy with a highly variable clinical presentation and currently unpredictable progression. This variability and unpredictability presents difficulties for prognostication and clinical trial design. [...]
2021 - 10.1002/ana.26044
Annals of neurology, Vol. 89 Núm. 5 (may 2021) , p. 967-978
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
